Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Eisai Responds: Decision to Remove Halaven Therapy from CDF

By R&D Editors | January 8, 2015

Eisai announced its extreme disappointment that the National Cancer Drugs Fund (NCDF) panel has apparently made the decision to remove Halaven(eribulin) from the Cancer Drugs Fund (CDF), following a process of arbitrary evaluation. The decision failed to recognize the overall survival benefit of eribulin, putting a flawed and inconsistent methodological process before the overall survival benefit for people living with terminal cancer. The news is particularly devastating for the thousands of women living with secondary breast cancer in the UK who could benefit from this innovative life-extending treatment.
 
“Access to the CDF has ensured that drugs like eribulin have become the standard of care for women with metastatic breast cancer in England. This evaluation now means that these women can no longer be treated with the drugs thousands before them have benefited from,” said Dr. Vivek Misra, Consultant in Clinical Oncology at The Christie, Manchester.
 
Metastatic breast cancer is a very difficult condition to treat and only 13 percent of women will survive beyond five years. Eribulin remains the only single agent chemotherapy to significantly improve overall survival in women with advanced breast cancer after anthracycline and taxane treatment. To date, eribulin is the sixth most prescribed treatment in the CDF and has been used by more than 2,000 women in England since 2011.
 
Eribulin is indicated for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. 
 
“Eribulin is an effective drug and thanks to the Cancer Drugs Fund, I have been able to prescribe it extensively to my patients. I have witnessed first-hand the positive impact the treatment can have on women living with metastatic breast cancer, both in quality of life and overall life extension,” commented Dr Hartmut Kristeleit, Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust.
 
“The NCDF decision implies that doctors have spent years prescribing ineffective treatments to patients, at an obvious cost to the NHS. I do not believe this is the case, nor would eribulin have received Marketing Authorization Approval here and across the world without very sound clinical data. It’s for this reason that I believe the decision is a mistake,” said Dr. Chris Twelves, Professor of Clinical Cancer Pharmacology and Oncology, and Honorary Consultant in Medical Oncology at the University of Leeds and St. James’s Institute of Oncology, who presented the benefits of eribulin to the NCDF panel.
 
“To say that we are disappointed by this decision would be a gross understatement; we are outraged. We will engage in further dialogue with the NCDF and NHS England and firmly stand by the clinical efficacy of eribulin. We would like to ask the Prime Minister for a pause in the process and now call on the Government to stop arbitrarily de-listing these drugs and allow women with secondary breast cancer to continue to benefit from these treatments,” commented Gary Hendler, President & CEO Eisai EMEA and President, Eisai Oncology Global Business Unit.
 
The NCDF decision is particularly regrettable given the need for direct foreign investment into the UK and may ultimately mean Eisai is forced to scale back its operations in the country. This news comes just weeks after Eisai opened a new multi-million pound manufacturing plant for a new cancer treatment in Hatfield, Hertfordshire.
 
Eribulin was first approved and launched in the UK in 2011 and Marketing Authorisation Approval was extended for earlier use in advanced breast cancer from the European Commission on 3 July 2014. Eribulin is currently approved in more than 55 countries around the world including all of the European Union, Canada, United States, Russia, Switzerland, South Korea, Japan and Singapore.
 
Source: Eisai

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE